Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in
participants with mixed dyslipidemia. Participants will receive 2 subcutaneous injections of
ARO-ANG3 or placebo.